Networks in Neurology: New Agents and Strategies for Migraine - Final Assessment
1.25 AMA PRA Category 1 Credit(s) ™
January 15, 2021
The accreditation for this activity has expired.
Primary Audience:
This activity is intended for neurologists involved in the care of patients with headache disorders.
Shivang Joshi, MD, MPH (Chair)
Shivang Joshi, MD, MPH (Chair)
Associate Professor of Clinical Pharmacy Practice, University of Buffalo School of Pharmacy
Neurologist/Headache Specialist, DENT Neurological Institute
Amherst, New York
Dr. Joshi has a B.Pharm from St. John’s University College of Pharmacy as well as an M.D. and M.P.H. from St. George’s University School of Medicine. He completed his neurology residency at the Beth Israel Medical Center in New York followed by a fellowship in Headache Medicine at Brigham and Women’s Hospital in Boston. While in Boston, he was also an Instructor of Neuroscience at the Harvard Medical School. He is Board certified in Neurology and Headache Medicine which he currently practices at the DENT Neurologic Institute. He is also a preceptor and Associate Clinical Professor of Clinical Pharmacy at University of Buffalo School of Pharmacy.
Ira Turner, MD (Surveyed Expert, Group Leader)
Chief
The Center for Headache Care and Research at
Island Neurological Associates, P.C.
Plainview, New York
A life-long New Yorker, Dr. Turner completed undergraduate work and research in chemistry at SUNY Binghamton followed by medical education at SUNY Downstate Medical Center. He completed both his internship in internal medicine and neurology residency at Nassau County Medical Center. From there, Dr. Turner became a founding partner of Island Neurological Associates in Plainview, NY and later chief of the division of neurology at Plainview Hospital. In 2000, he started the Center for Headache Care and Research at Island Neurological Associates focusing on clinical trials for treatment of episodic and chronic migraine as well as cluster headache and post-herpetic neuralgia. Over the years, he has held a broad variety of additional roles spanning education, research, mentorship, and consulting.Jessica Ailani, MD (Surveyed Expert, Group Leader)
Professor of Neurology, Georgetown University Hospital
Director, MedStar Georgetown Headache Center
Washington, DC
Jessica Ailani, MD, is a Professor of Clinical Neurology and Director of the Medstar Georgetown Headache Center in Washington, DC. She received her medical degree from the Stony Brook University School of Medicine in New York followed by an internship at Winthrop University Hospital. Dr. Ailani completed a residency and Chief Residency in Neurology at NYU Langone Medical Center and a fellowship in Headache Medicine at Thomas Jefferson University in Philadelphia. She is board-certified in Neurology with subspecialty certification in Headache Medicine. She is also a fellow of the American Headache Society and of the American Academy of Neurology. She has held a variety of positions on academic journals and leadership boards.Wade Cooper, DO (Surveyed Expert, Group Leader)
Clinical Associate Professor of Neurology
Clinical Associate Professor in Anesthesiology
Director, Headache & Neuropathic Pain
University of Michigan School of Medicine
Ann Arbor, Michigan
Dr. Wade Cooper obtained his medical degree from Michigan State University’s (MSU) College of Osteopathic Medicine followed by residency in neurology at the MSU/Sparrow Health System in. He completed a fellowship in Headache Medicine at the Michigan Head Pain & Neurological Institute and holds a United Council for Neurologic Subspecialties (UCNS) board certification in Headache Medicine.
Dr Cooper is currently the Director of Headache & Neuropathic Pain as well as a Clinical Associate Professor in Neurology and Anesthesiology at the University of Michigan. His primary areas of interest include the relationship of inflammation to centralized pain and autonomic dysfunction as well as interventional treatments in headache.
Emad Estemalik, MD (Group Leader)
Section Head - Headache Medicine / Clinical Assistant Professor of Medicine
Cleveland Clinic
Rocky River, OH
Emad Estemalik MD, MBA is the Section Head for Headache and Facial Pain at the Center for Neurological Restoration at the Cleveland Clinic and is board certified in Headache Medicine. He received his MD from Ain Shams University in Cairo, Egypt, and his MBA from Case Western Reserve University. From there, he completed his residency and fellowship in Headache Medicine at the Cleveland Clinic. He is also a member of the American Headache Society.
Dr. Estemalik speaks multiple languages (Arabic, German, French, and Spanish) and often takes care of international patients. He also serves on Cleveland Clinic’s Global Patient Services Advisory Board. His areas of interest include migraine headaches, trigeminal autonomic cephalgias, and facial neuralgias for which he is a national and international speaker as well as an active participant in clinic trials. Additionally, he is an active reviewer for multiple journals such as the Cleveland Clinic Journal of Medicine, Pain Practice, and the Egyptian Journal of Neurology and Neurosurgery.
Christopher Gottschalk, MD (Group Leader)
Director, Headache Medicine
Chief, Division of General Neurology
Yale University
New Haven, Connecticut
Dr. Gottschalk began training in Headache Medicine (HM) at the Montefiore Headache Unit in the 1990s under Seymour Solomon, Richard Lipton, and Lawrence Newman. He is passionate about education regarding HM because it encompasses every important aspect of medical practice: fascinating and complex physiology and pharmacology, diverse and subtle clinical syndromes, enormously rewarding relationships with patients; at the same time, the challenges are stimulating and informative, whether addressing cognitive errors and biases that interfere with care or addressing stigma, disparities in access and care, and policies that limit the potential growth of our discipline.Accreditation Information
This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC.
|
| Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Designation Statement PIM designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™, which will be received at the end of the Final Assessment module. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
Disclosures
Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.
Dr. Ailani reports the following financial relationships:
- Consulting fees: Allergan/Abbvie, Axsome Therapeutics, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Satsuma Pharmaceuticals Inc., Teva Pharmaceuticals, Theranica
- Contracted research: Allergan/Abbvie, Biohaven Pharmaceuticals Inc., Satsuma Pharmaceuticals Inc., Zosano Pharma
- Fees for Non-CME/CE Services: Allergan/Abbvie, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Teva Pharmaceuticals
- Stock options: Ctrl M Health
Dr. Cooper reports the following financial relationships
- Consulting fees: Amgen, Dolor Technologies, Lilly, Lundbeck, Teva Pharmaceuticals, Theranica
- Ownership interest: Dolor Technologies
Dr. Joshi reports the following financial relationships:
- Consulting fees: Allergan, Amgen, Biohaven Pharmaceuticals Inc., Lilly, Teva Pharmaceuticals
Dr. Smith reports the following financial relationships:
- Consulting fees: Allergan
- Fees for Non-CME/CE Services: Allergan, Amgen, Lilly, Teva
Dr. Turner reports the following financial relationships:
- Consulting fees: Allergan, Amgen, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Novartis Pharmaceuticals Corp., Revance Therapeutics Inc., Teva Pharmaceuticals, Theranica
- Contracted research: Allergan, Lilly, Teva Pharmaceuticals, Theranica
Dr. Estemalik reports the following financial relationships:
- Consulting fees: Lilly, Lundbeck
- Contracted research: Lilly
- Fees for Non‐CME/CE Services: Allergan, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Teva
- Pharmaceuticals
- Consulting fees: Alder/Lundbeck, Amgen/Novartis, Axsome, Biohaven, Spherix Global Insights, Theranica, Upsher Smith, Vorso
- Fees for Non‐CME/CE Services: Amgen/Novartis, Allergan/AbbVie, Biohaven, Lilly, Theranica, Upsher Smith
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Commercial Support
This activity is supported by educational grants from Lilly and Teva Pharmaceuticals.
